Results for tag: "Penicillin Binding Proteins"

Penicillin-binding proteins (PBPs) are a group of enzymes found in the cell wall biosynthesis pathway of bacteria. These proteins are targets for β-lactam antibiotics, which include penicillins, cephalosporins, monobactams, and carbapenems. The market for agents targeting PBPs typically revolves around the development and production of antibiotics that can inhibit the function of these proteins, which is pivotal in the synthesis of bacterial cell walls, ultimately causing cell lysis and death. As bacterial resistance to antibiotics has increased, research within this market has focused on discovering new β-lactam compounds with higher affinity for PBPs or developing adjuvants that can inhibit resistance mechanisms. The market is also engaged in the development of diagnostic tools to identify bacterial strains and their respective PBPs, aiding in the selection of appropriate antibiotic therapies. Several pharmaceutical companies participate in the Penicillin Binding Proteins market to develop and provide a diverse range of antibiotic treatments. These companies include but are not limited to Pfizer, Merck & Co., GlaxoSmithKline, Novartis, and AstraZeneca. These entities are involved in the continuous process of research, development, and commercialization of antibacterial agents targeting PBPs as well as in advancements to curb antibiotic resistance and enhance the efficacy of existing treatments. Show Less Read more